Wang K, Zheng R, Chen Y, et al. - Researchers conducted this prospective cohort study to determine the clinical safety and effectiveness of cervical intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy, on house dust mite induced allergic rhinitis (AR) in adults, by comparing the symptom scores, quality-of-life scores and drug scores (use of rescue medication) before and after treatment. Side events have also been recorded in the meantime. The authors discovered that no moderate-severe adverse events were caused by cervical ILIT. Compared with the baseline, individuals receiving cervical ILIT experienced a significant improvement in nasal symptoms, eye symptoms and quality of life. There has also been evidence of a decrease in the use of rescue medication. After three injections, cervical ILIT has been shown to be safe and induced tolerance of allergens in this first-in-human clinical study.